Intelligence Profile
Safety Profile
Evidence Limitation Notice: Clinical evidence for the combination of CJC-1295 + Ipamorelin + AOD-9604 is extremely limited. Available evidence comes from only two recent review articles (2026) focused on peptide therapies in sports medicine and orthopedics, with no dedicated clinical trials specifically evaluating this triple combination.
Known Side Effects
Based on the limited available evidence, individual peptides in this combination may cause:
Growth hormone-related effects (primarily from CJC-1295 and Ipamorelin):
- Injection site reactions (pain, redness, swelling)
- Water retention and mild edema
- Joint stiffness or discomfort
- Potential changes in blood glucose levels
- Headache and dizziness
Specific concerns flagged in the available literature include the potential for excessive growth hormone stimulation when multiple growth hormone-releasing compounds are combined, though specific data on this triple combination is lacking.
Contraindications
The evidence suggests these peptides should be avoided in individuals with:
- Active malignancy or history of cancer (growth hormone may promote tumor growth)
- Severe kidney or liver disease
- Known hypersensitivity to any component
Critical evidence gap: No studies have specifically evaluated contraindications for this particular combination therapy.
Drug Interactions
Evidence is extremely thin regarding drug interactions. Theoretical concerns include:
- Medications affecting blood glucose (potential interaction with diabetes medications)
- Other hormone therapies
- Medications metabolized by the liver
High-Risk Populations
Based on limited available evidence, the following populations should avoid this combination:
- Pregnant or breastfeeding women
- Children and adolescents (due to potential interference with natural growth hormone patterns)
- Individuals with diabetes (due to potential glucose metabolism effects)
- Patients with cardiovascular disease (limited safety data)
Important Safety Considerations
Regulatory status: These peptides are not FDA-approved for the uses commonly promoted, and their manufacturing quality and purity may vary significantly between sources.
Long-term safety: No long-term safety data exists for this combination therapy.
Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any peptide therapy, especially combination treatments with limited clinical evidence.